Trial With Taxotere and Cisplatin in Non-operable Adrenocortical Carcinoma

Learn more about:
Related Clinical Trial
The Impact of Mitotane Therapy on Serum Free Proteins in Patients With Adrenocortical Carcinoma Phase II Trial of Pembrolizumab Plus Lenvatinib in Advanced Adrenal Cortical Carcinoma Natural History Study of Children and Adults With Adrenocortical Cancer (ACC) Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors Combination Chemotherapy With Suramin Plus Doxorubicin in Treating Patients With Advanced Solid Tumors Natural History Study of Infants With Adrenal Masses Found on Prenatal and/or Neonatal Imaging Cisplatin-Based Chemotherapy and/or Surgery in Treating Young Patients With Adrenocortical Tumor International Pediatric Adrenocortical Tumor Registry Antineoplaston Therapy in Treating Patients With Stage IV Adrenal Gland Cancer Structured Evaluation of adRENal Tumors Discovered Incidentally – Prospectively Investigating the Testing Yield Evaluation of 123I-Iodometomidate for Adrenal Scintigraphy Sorafenib Plus Paclitaxel in Adreno-Cortical-Cancer Patients Efficacy of Adjuvant Mitotane Treatment (ADIUVO) Possible New Therapy for Advanced Cancer IMC-A12 With Mitotane vs Mitotane Alone in Recurrent, Metastatic, or Primary ACC That Cannot Be Removed by Surgery Studying Genes in Samples From Younger Patients With Adrenocortical Tumor Single Agent Pembrolizumab in Subjects With Advanced Adrenocortical Carcinoma Gossypol Acetic Acid in Treating Patients With Recurrent, Metastatic, or Primary Adrenocortical Cancer That Cannot Be Removed By Surgery Evaluation of Side Effects of Mitotane Optimal Methods of Disease Progression and Survival Analysis in Children and Adults Patients With Adrenocortical Cancer (ACC) Surgery and Heated Chemotherapy for Adrenocortical Carcinoma Sunitinib in Refractory Adrenocortical Carcinoma Nivolumab in Treating Patients With Metastatic Adrenocortical Cancer Phase II Study for Combination of Camrelizumab and Apatinib in the Second-line Treatment of Recurrent or Metastatic Adrenocortical Carcinoma Phase 1 Study of ATR-101 in Subjects With Advanced Adrenocortical Carcinoma Treatment Study Using Bevacizumab for Patients With Adrenocortical Carcinoma Adjuvant Chemotherapy vs. Observation/Mitotane After Primary Surgical Resection of Localized Adrenocortical CarcInoma A Study of OSI-906 in Patients With Locally Advanced or Metastatic Adrenocortical Carcinoma Surgery and Heated Intraperitoneal Chemotherapy for Adrenocortical Carcinoma S9427, Suramin in Treating Patients With Stage III or Stage IV Adrenocortical Cancer Incurable by Surgery Natural History and Tissue Acquisition Study of Adrenocortical Carcinoma Cabozantinib in Advanced Adrenocortical Carcinoma Trial With Taxotere and Cisplatin in Non-operable Adrenocortical Carcinoma German Adrenocortical Carcinoma Registry Clinical Trial of Dovitinib in First-line Metastatic or Locally Advanced Non-resectable Adrenocortical Carcinoma

Brief Title

Trial With Taxotere and Cisplatin in Non-operable Adrenocortical Carcinoma

Official Title

Phase II Trial With Taxotere and Cisplatin in Non-operable Adrenocortical Carcinoma

Brief Summary

      The trial is a phase II trial in adrenocortical carcinoma (ACC), a rare malignancy with poor
      prognosis. It will provide results leading to the establishment of the effect of the included
      drugs. The regimen consists of cisplatin plus taxotere. Over a period of 1-2 years this
      national trial will include 19-36 patients with advanced ACC from different centres in
      Denmark. Patients not responding to the first line treatment will be switched to the
      alternative regimen. The primary objective of this trial is to investigate response rate.
      Secondary endpoints are survival, time to progression, best overall response rate and
      duration of response.

Detailed Description

      Treatment every three weeks, evaluation after 2 cycles, CTC criterias used for toxicity

Study Phase

Phase 2

Study Type


Primary Outcome

response rate

Secondary Outcome

 Survival, time to progression, best overall response rate and duration of response


Adrenocortical Carcinoma


cisplatin, taxotere

Study Arms / Comparison Groups

Description:  taxotere and cisplatin day one every three weeks


* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Recruitment Status


Estimated Enrollment


Start Date

April 2006

Completion Date

February 2012

Primary Completion Date

February 2012

Eligibility Criteria

        Inclusion Criteria:

          -  Histologically confirmed diagnosis of adrenocortical carcinoma

          -  Locally advanced or metastatic disease not amenable to radical surgery resection
             (Stage III-IV)

          -  Radiologically measurable disease

          -  ECOG performance status 0-2

          -  Life expectancy > 3 months

          -  Age ≥18 years

          -  Adequate bone marrow reserve (neutrophils > 1500/mm3 and platelets > 100,000/mm3)

          -  Effective contraception in pre-menopausal female and male patients

          -  Patient's written informed consent

          -  Ability to comply with the protocol procedures (including availability for follow-up

          -  Previous palliative surgery, radiotherapy or radiofrequency ablation is acceptable as
             long as radiologically monitorable disease is verifiable afterwards.

        Exclusion Criteria:

          -  History of prior malignancy, except for cured non-melanoma skin cancer, curatively in
             situ cervical carcinoma, or other cancers treated with no evidence of disease for at
             least five years.

          -  Previous cytotoxic chemotherapy for adrenocortical carcinoma

          -  Renal insufficiency (serum creatinine ≥2 mg/dl or creatinine clearance ≤ 60 ml/min)

          -  Hepatic insufficiency (serum bilirubin ≥2 x the institutional upper limit of normal
             range and/or serum transaminases ≥ 3 x the institutional upper limit of normal range;
             exception: in patients on mitotane, transaminase levels up to 5 x the institutional
             upper limit of normal range are acceptable)

          -  Pregnancy or breast feeding

          -  Known hypersensitivity to any drug included in the treatment protocol

          -  Presence of active infection

          -  Any other severe clinical condition that in the judgment of the local investigator
             would place the patient at undue risk or interfere with the study completion

          -  Current treatment with other experimental drugs and/or previous participation in
             clinical trials with other experimental agents for adrenocortical carcinoma




18 Years - N/A

Accepts Healthy Volunteers



Gedske Daugaard, M.D., DMSc, , 

Location Countries


Location Countries


Administrative Informations



Organization ID

02 262098

Responsible Party

Principal Investigator

Study Sponsor

Rigshospitalet, Denmark

Study Sponsor

Gedske Daugaard, M.D., DMSc, Principal Investigator, Rigshospitalet, Denmark

Verification Date

February 2012